Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
W STEP-1 (RCT wieloorodkowy, faza 3) raportowano redni redukcj masy ciaa o okoo 14,9% przy 68 tygodniach interwencji semaglutydem 2,4 mg tygodniowo vs placebo
doi:10.1111/dom.13487 Sun F, Wu S, Wang J, et al
TRIUMPH-1 (NCT05929066), the Phase 3 registration trial for the obesity indication, reported topline results on May 21, 2026 : average weight loss of 28.3% at 80 weeks at the highest dose in 2,339 participants, versus 2.2% on placebo, and 30.3% at 104 weeks among participants with a BMI of 35 or above who continued in a pre-specified extension
While these medications effectively reduce body weight, not all weight lost represents fat tissue
Suitability of 3D human brain spheroid models to distinguish toxic effects of gold and poly-lactic acid nanoparticles to assess biocompatibility for brain drug delivery
